Matches in SemOpenAlex for { <https://semopenalex.org/work/W3037634475> ?p ?o ?g. }
- W3037634475 endingPage "1466" @default.
- W3037634475 startingPage "1461" @default.
- W3037634475 abstract "Background No real-life study on the comparative effectiveness of Vedolizumab (VDZ), Adalimumab (ADA), and Golimumab (GOL) in ulcerative colitis (UC) is currently available. Aims To compare the effectiveness of the three biologics in consecutive patients with UC. Methods A three-arms propensity score-adjusted analysis was performed using the Inverse Probability of Treatment Weighting method. Results 463 treatments (VDZ: n = 187; ADA: n = 168; GOL: n = 108) were included (median follow-up: 47.6 weeks). At 12 weeks (n = 463), a steroid-free remission was reported in 24.1% patients in the VDZ group, in 33.3% patients in the ADA group, and in 30.6% patients in the GOL group (p = n.s. for all comparisons). At 52 weeks (n = 377), a steroid-free remission was reported in 51.5% patients in the VDZ group, in 31.2% patients in the ADA group, and in 29.4% patients in the GOL group (p = 0.002 for VDZ vs. ADA, p = 0.001 for VDZ vs. GOL, p = n.s. for ADA vs. GOL). Cox survival analysis demonstrated that patients treated with VDZ had reduced probability of treatment discontinuation compared to those treated with ADA (HR: 0.42, 95% CI 0.28–0.64, p < 0.001) and GOL (HR: 0.30, 95% CI 0.19–0.46, p < 0.001), while patients treated with ADA had reduced risk of treatment discontinuation compared to those treated with GOL (HR: 0.71, 95% CI 0.50–1.00, p = 0.048). Conclusions VDZ was superior to ADA and GOL at 52 weeks and as treatment persistence, while ADA showed a superior treatment persistence compared to GOL." @default.
- W3037634475 created "2020-07-02" @default.
- W3037634475 creator A5000268699 @default.
- W3037634475 creator A5003162215 @default.
- W3037634475 creator A5007719681 @default.
- W3037634475 creator A5008838958 @default.
- W3037634475 creator A5010932748 @default.
- W3037634475 creator A5016678827 @default.
- W3037634475 creator A5018141422 @default.
- W3037634475 creator A5025089101 @default.
- W3037634475 creator A5029574178 @default.
- W3037634475 creator A5044608835 @default.
- W3037634475 creator A5052840053 @default.
- W3037634475 creator A5054320006 @default.
- W3037634475 creator A5065032176 @default.
- W3037634475 creator A5066032102 @default.
- W3037634475 creator A5067231655 @default.
- W3037634475 creator A5068693559 @default.
- W3037634475 creator A5070847739 @default.
- W3037634475 creator A5075167160 @default.
- W3037634475 creator A5080410805 @default.
- W3037634475 creator A5081551616 @default.
- W3037634475 creator A5087980427 @default.
- W3037634475 creator A5088248608 @default.
- W3037634475 date "2020-12-01" @default.
- W3037634475 modified "2023-10-17" @default.
- W3037634475 title "A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis" @default.
- W3037634475 cites W1999822211 @default.
- W3037634475 cites W2034795132 @default.
- W3037634475 cites W2036193982 @default.
- W3037634475 cites W2048470090 @default.
- W3037634475 cites W2050886412 @default.
- W3037634475 cites W2103371988 @default.
- W3037634475 cites W2110818436 @default.
- W3037634475 cites W2142495742 @default.
- W3037634475 cites W2175886073 @default.
- W3037634475 cites W2232409882 @default.
- W3037634475 cites W2515296740 @default.
- W3037634475 cites W2580577961 @default.
- W3037634475 cites W2789272024 @default.
- W3037634475 cites W2793180767 @default.
- W3037634475 cites W2808595848 @default.
- W3037634475 cites W2809113401 @default.
- W3037634475 cites W2886144609 @default.
- W3037634475 cites W2898518424 @default.
- W3037634475 cites W2934056601 @default.
- W3037634475 cites W2976731348 @default.
- W3037634475 doi "https://doi.org/10.1016/j.dld.2020.06.014" @default.
- W3037634475 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32601033" @default.
- W3037634475 hasPublicationYear "2020" @default.
- W3037634475 type Work @default.
- W3037634475 sameAs 3037634475 @default.
- W3037634475 citedByCount "16" @default.
- W3037634475 countsByYear W30376344752021 @default.
- W3037634475 countsByYear W30376344752022 @default.
- W3037634475 countsByYear W30376344752023 @default.
- W3037634475 crossrefType "journal-article" @default.
- W3037634475 hasAuthorship W3037634475A5000268699 @default.
- W3037634475 hasAuthorship W3037634475A5003162215 @default.
- W3037634475 hasAuthorship W3037634475A5007719681 @default.
- W3037634475 hasAuthorship W3037634475A5008838958 @default.
- W3037634475 hasAuthorship W3037634475A5010932748 @default.
- W3037634475 hasAuthorship W3037634475A5016678827 @default.
- W3037634475 hasAuthorship W3037634475A5018141422 @default.
- W3037634475 hasAuthorship W3037634475A5025089101 @default.
- W3037634475 hasAuthorship W3037634475A5029574178 @default.
- W3037634475 hasAuthorship W3037634475A5044608835 @default.
- W3037634475 hasAuthorship W3037634475A5052840053 @default.
- W3037634475 hasAuthorship W3037634475A5054320006 @default.
- W3037634475 hasAuthorship W3037634475A5065032176 @default.
- W3037634475 hasAuthorship W3037634475A5066032102 @default.
- W3037634475 hasAuthorship W3037634475A5067231655 @default.
- W3037634475 hasAuthorship W3037634475A5068693559 @default.
- W3037634475 hasAuthorship W3037634475A5070847739 @default.
- W3037634475 hasAuthorship W3037634475A5075167160 @default.
- W3037634475 hasAuthorship W3037634475A5080410805 @default.
- W3037634475 hasAuthorship W3037634475A5081551616 @default.
- W3037634475 hasAuthorship W3037634475A5087980427 @default.
- W3037634475 hasAuthorship W3037634475A5088248608 @default.
- W3037634475 hasConcept C126322002 @default.
- W3037634475 hasConcept C17923572 @default.
- W3037634475 hasConcept C2776207728 @default.
- W3037634475 hasConcept C2778715236 @default.
- W3037634475 hasConcept C2779134260 @default.
- W3037634475 hasConcept C2780132546 @default.
- W3037634475 hasConcept C2780479503 @default.
- W3037634475 hasConcept C2781290027 @default.
- W3037634475 hasConcept C71924100 @default.
- W3037634475 hasConcept C90924648 @default.
- W3037634475 hasConceptScore W3037634475C126322002 @default.
- W3037634475 hasConceptScore W3037634475C17923572 @default.
- W3037634475 hasConceptScore W3037634475C2776207728 @default.
- W3037634475 hasConceptScore W3037634475C2778715236 @default.
- W3037634475 hasConceptScore W3037634475C2779134260 @default.
- W3037634475 hasConceptScore W3037634475C2780132546 @default.
- W3037634475 hasConceptScore W3037634475C2780479503 @default.
- W3037634475 hasConceptScore W3037634475C2781290027 @default.
- W3037634475 hasConceptScore W3037634475C71924100 @default.